This shift in the immune contexture of the TME ultimatelyresulted in robust antitumor efficacy in an EO771 breast cancer model,as evidenced by inhibition of tumor growth and increased survivalbenefit, with approximately 40% of mice exhibiting complete responsesand durable immunological memory that protected against tumor rechallenge.We also found that SAPCon[100 kDa] was effective in a challenging4T1 model of triple-negative breast cancer in combination with currentlyapproved anti-PD-1 ICB. Here, PDCD1 is linked to triple-negative breast carcinoma.